Search
News & Events
The Kids Research Institute Australia researchers share in State Government science grantsFour The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.
News & Events
New drug hope for babies with leukaemiaResearchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.
News & Events
A cell change that drives leukaemiaIt is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.
News & Events
WA families to help find triggers for childhood leukaemiaWest Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.
Research
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaOur study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia
Research
Bilateral murine tumor models for characterizing the response to immune checkpoint blockadeThis protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade
Research
Sensitizing the Tumor Microenvironment to Immune Checkpoint TherapyIn this review we explore the current literature about the predictive characteristics of the tumor microenvironment and discuss therapeutic approaches
Research
Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemiaThe aim of our study was to investigate whether CBL0137 has potential as a therapeutic and chemopotentiating compound in MLL-r leukemia
Research
Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG RegistryThese findings provide a compelling argument for efforts to reduce exposure of the brainstem in the treatment of medulloblastoma
Research
Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade gliomaBevacizumab is well tolerated and appears most effective for rapid tumor control to preserve vision and improve morbidity